Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022

Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
doi: https://doi.org/10.1101/2023.02.08.23285643

Article Information

doi 
https://doi.org/10.1101/2023.02.08.23285643
History 
  • February 13, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Anne J. Huiberts1,
  2. Brechje de Gier1,
  3. Christina E. Hoeve1,
  4. Hester E. de Melker1,
  5. Susan J.M. Hahné1,
  6. Gerco den Hartog1,2,
  7. Janneke H.H.M. van de Wijgert1,3,
  8. Susan van den Hof1 and
  9. Mirjam J. Knol1,*
  1. 1Centre for Infectious Disease Control, National Institute for Public Health and Environment (RIVM), Bilthoven, the Netherlands
  2. 2Radboud Center for Infectious Diseases, Radboudumc, Nijmegen, the Netherlands
  3. 3Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands
  1. ↵* Corresponding author; email: mirjam.knol{at}rivm.nl
Back to top
Posted February 13, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, Hester E. de Melker, Susan J.M. Hahné, Gerco den Hartog, Janneke H.H.M. van de Wijgert, Susan van den Hof, Mirjam J. Knol
medRxiv 2023.02.08.23285643; doi: https://doi.org/10.1101/2023.02.08.23285643
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area